Scientists developing vaccines and anti-tick treatments amid growing concern over spread of disease ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

The following companies are leading this vector-borne boon, each tackling the problem from a different technological angle: ...

Since pharmaceutical companies Pfizer and Valneva announced positive results from their phase 3 trial of a vaccine to prevent Lyme disease last month, two questions have loomed large: Will the vaccine ...

Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...

Pfizer and Valenva are seeking regulatory approval from the Food and Drug Administration for a Lyme disease vaccine in development that's more than 70% effective against the tick-borne illness.

This week, Pfizer and French vaccine company, Valneva, released phase 3 clinical trial data for PF-0730740, a four-dose Lyme disease vaccine they developed together that is about 70% effective. While ...

Pfizer shared an update last week on its clinical trial for VALOR, which is short for "Vaccine Against Lyme for Outdoor Recreationists." The drugmaker said in its report that the vaccine was ...

As more people spend time outdoors with the unofficial start of summer ahead, experts are warning about the dangers that ...

Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine showed more than 70% efficacy in late-stage clinical trials. The candidate, ...

Experts recommend wearing protective clothing, using insect repellent and checking for ticks after spending time outdoors.